Status:
COMPLETED
Impact of Exenatide on Sleep in Type 2 Diabetes
Lead Sponsor:
University of Chicago
Conditions:
Type 2 Diabetes
Sleep Disordered Breathing
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The investigators propose a pilot study to test the novel hypothesis that Exenatide treatment in patients with type 2 diabetes results in improved sleep duration and quality and to explore the relatio...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of T2DM based on physician documentation according to established guidelines will be eligible.
Exclusion
- Patients with unstable cardiac, neurological or psychiatric disease
- Women who are pregnant or report trying to get pregnant will be excluded.
- Patients treated for obstructive sleep apnea (OSA) will be excluded.
- Patients with established OSA will be included only if they have declined treatment of OSA.
- Patients with morbid obesity (BMI ≥ 40 gk/m2)
- Patients on insulin
- Patients already taking an incretin-based drug will not be included
- Patients with renal disease (creatinine clearance \<30 ml/min), gastroparesis and history of pancreatitis will also be excluded based on known possible adverse medication side effects.
- Patients taking an insulin secretagogue will be excluded.
- Patients with Hemoglobin A1c values greater than or equal to 10 will be excluded.
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01136798
Start Date
June 1 2010
End Date
September 1 2016
Last Update
September 12 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Chicago
Chicago, Illinois, United States, 60637
2
University of Chicago
Chicago, Illinois, United States, 60637